ID   HCC-1.1
AC   CVCL_0C52
SY   HCC.1.1; HCC1.1; 3SP; 3sp
DR   Cosmic; 1628381
DR   Cosmic; 2162522
DR   Wikidata; Q54881504
RX   PubMed=18594539;
RX   PubMed=21364009;
RX   PubMed=23887712;
WW   Info; LCCL; -; https://lccl.zucmanlab.com/hcc/cellLines/HCC.1.1
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C42 ! BLC-1
OI   CVCL_0C53 ! HCC-1.2
OI   CVCL_0C47 ! MF-1 [Human]
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-04-25; Version: 9
//
RX   PubMed=18594539; DOI=10.1038/sj.bjc.6604440; PMCID=PMC2453035;
RA   Sagmeister S., Eisenbauer M., Pirker C., Mohr T., Holzmann K.,
RA   Zwickl H., Bichler C., Kandioler-Eckersberger D., Wrba F., Mikulits W.,
RA   Gerner C., Shehata M., Majdic O., Streubel B., Berger W., Micksche M.,
RA   Zatloukal K., Schulte-Hermann R., Grasl-Kraupp B.;
RT   "New cellular tools reveal complex epithelial-mesenchymal interactions
RT   in hepatocarcinogenesis.";
RL   Br. J. Cancer 99:151-159(2008).
//
RX   PubMed=21364009; DOI=10.1158/1535-7163.MCT-10-0917;
RA   van Zijl F., Mall S., Machat G., Pirker C., Zeillinger R.,
RA   Weinhaeusel A., Bilban M., Berger W., Mikulits W.;
RT   "A human model of epithelial to mesenchymal transition to monitor drug
RT   efficacy in hepatocellular carcinoma progression.";
RL   Mol. Cancer Ther. 10:850-860(2011).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//